-
Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD stud
Author: Trotman, J.; Bouabdallah, K.; Bijou, F.; Sálek, D.; de Oliveira, A. C.; Song, Y.; Kingsley, E. C.; Flowers, C. R.; Liao, S.; Huang, S.; Shah, N.; Dumartin, L.; Zinzani, P. L
Journal: ESMO OPEN. 2026; Vol. 11, Issue 4, pp. -. DOI: 10.1016/j.esmoop.2026.106942
-
Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austri
Author: Dobric, N.; Hasenleithner, S. O.; Suppan, C.; Klocker, E. V; Hlauschek, D.; Graf, R.; Beichler, C.; Albertini, C.; Egle, D.; Liu, D.; Starzer, A. M.; Bartsch, R.; Moser, T.; Rinnerthaler, G.; Jost, P. J.; Heitzer, E.; Dandachi, N.; Balic, M
Journal: ESMO OPEN. 2026; Vol. 11, Issue 4, pp. -. DOI: 10.1016/j.esmoop.2026.106939
-
Letter Re: Artificial intelligence-powered realtime multimodal model for predicting recurrence and survival in head and neck cancer: a multicenter, multinational stud
Author: Li, N.; Liu, X.; Zhang, S
Journal: ESMO OPEN. 2026; Vol. 11, Issue 4, pp. -. DOI: 10.1016/j.esmoop.2026.106943
-
Association of comprehensive inflammatory-metabolic status and perioperative outcomes in gastric cancer: insights from four randomized controlled trial
Author: Zhang, L. -K.; Shang-Guan, Z. -X.; Zheng, H. -L.; Zheng, H. -H.; Zheng, C. -Y.; Chen, W. -F.; Xie, J. -W
Journal: ESMO OPEN. 2026; Vol. 11, Issue 4, pp. -. DOI: 10.1016/j.esmoop.2026.106922
-
Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancie
Author: Zhu, J.; Li, J.; Tam, C. S.; Wang, L.; Xu, J.; Zhang, J.; Khanna, P.; Qiu, L
Journal: ESMO OPEN. 2026; Vol. 11, Issue 4, pp. -. DOI: 10.1016/j.esmoop.2026.106086
-
A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) stud
Author: Y. Ryu, S.; Nam, B. H.; Kim, M. H.; Jang, W. I.; Sitathanee, C.; Linh, T. D.; Lee, K. H.; Lee, W. M.; Kim, E. T.; Kang, S. B.; Kim, J. H.; V. Park, J.; Lee, K. B.; Cho, C. H.; Lou, H.; Kim, Y. H.; Kim, Y. T.; Lee, Y. H.; Wu, X.; Kim, J. W.; Park, S. I.; Jeon, S.; Thinh, D. H.; Kry, S. F.; Gaffney, D.; Small, W.; Wilailak, S
Journal: ESMO OPEN. 2026; Vol. 11, Issue 4, pp. -. DOI: 10.1016/j.esmoop.2026.106102
-
Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asi
Author: Rugo, H. S.; Tolaney, S. M.; Cortes, J.; Marme, F.; de Azambuja, E.; Xu, B.; Sohn, J.; Naito, Y.; Valdez, T.; Gary, D.; Zhu, J.; Lai, C.; Bardia, A
Journal: ESMO OPEN. 2026; Vol. 11, Issue 4, pp. -. DOI: 10.1016/j.esmoop.2026.106905
-
A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cance
Author: Gong, C.; Zhao, Y.; Wang, L.; Cao, J.; Tao, Z.; Li, T.; Zhao, M.; Miao, H.; Hu, X.; Wang, B
Journal: ESMO OPEN. 2026; Vol. 11, Issue 4, pp. -. DOI: 10.1016/j.esmoop.2026.106889
